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Available online 2 December 2016Primary progressive aphasia (PPA) is a heterogeneous syndrome with various neuropathological causes for
which no medical treatment with proven efﬁcacy exists. Basal forebrain (BF) volume loss has been reported in
PPA but its relation to cholinergic depletion is still unclear. The primary objective of this study was to investigate
whether cholinergic alterations occur in PPA variants and how this relates to BF volume loss. An academic mem-
ory clinic based consecutive series of 11 PPApatients (ﬁvewith the semantic variant (SV), fourwith the logopenic
variant (LV) and two with the nonﬂuent variant (NFV)) participated in this cross-sectional in vivo PET imaging
study together with 10 healthy control subjects. Acetylcholinesterase (AChE) activity was quantitatively mea-
sured in the neo- and allocortex using N-[11C]-Methylpiperidin-4-yl propionate (PMP)-PET with arterial sam-
pling and metabolite correction. Whole brain and BF volumes were quantiﬁed using voxel-based
morphometry on high-resolution magnetic resonance imaging (MRI) scans.
In the PPA group, only LV cases showed decreases in AChE activity levels compared to controls. Surprisingly, a
substantial number of SV cases showed signiﬁcant AChE activity increases compared to controls. BF volume
did not correlate with AChE activity levels in PPA. To conclude, in our sample of PPA patients, LV but not SV
was associated with cholinergic depletion. BF atrophy in PPA does not imply cholinergic depletion.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Primary progressive aphasia1. Introduction
Primary progressive aphasia (PPA) is characterized by an isolated
language impairment and is divided clinically into the subtypes of
logopenic (LV), nonﬂuent (NFV) and semantic variant (SV) aphasia
(Gorno-Tempini et al., 2011; Vandenberghe, 2016). Of the LV cases,
50–60% have underlying Alzheimer's disease (AD) pathology. In
50–70% of NFV cases the underlying cause is frontotemporal lobar
degeneration (FTLD)-tauopathy (i.e. corticobasal degeneration
(CBD), progressive supranuclear palsy (PSP) or Pick's diseaseUniversity Hospitals Leuven,
ndenberghe).
. This is an open access article underpathology) and 69–83% of SV cases have FTLD-Transactive response
DNA binding Protein 43 kDa (TDP-43) type C pathology (Grossman,
2010; Vandenberghe, 2016). Cholinergic depletion has been docu-
mented in typical AD (Bohnen et al., 2005, 2003; Kuhl et al., 1999),
but it is currently unknown whether a cholinergic deﬁcit also occurs
in atypical AD presenting as PPA or in PPA due to a tauopathy or TPD-
43 proteinopathy.
According to MRI volumetric studies, the basal forebrain (BF) is
atrophic in PPA SV and NFV (Teipel et al., 2016, 2014), and mainly
so the posterior part of the nucleus basalis (Ch4) and nucleus
subputaminalis (NSP). The BF is the primary source of cholinergic
transmission to the neo- and allocortex (Zaborszky et al., 2015),
hence the hypothesis that a cholinergic deﬁcit may also exist in
non-AD cases of PPA.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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AD or on FTLD-tau. In AD, severe degeneration of the BF, mainly the pos-
terior part of Ch4, has been reported (Baker-Nigh et al., 2015; Grothe
et al., 2014; Kerbler et al., 2015; Teipel et al., 2005). In FTLD-tau, Ch4 de-
generation has been shown in PSP (Kasashima and Oda, 2003;
Tagliavini et al., 1984), whereas both degeneration (Kasashima and Oda,
2003) and preservation (Dickson, 1999) of Ch4 have been reported in
CBD.
Cholinergic denervation resulting from BF volume loss may be
reﬂected in altered AChE activity levels. AChE activity levels can be
mapped in vivo using N-[11C]-Methyl-4-piperidyl acetate ([11C]MP4A)-
or N-[11C]-Methylpiperidin-4-yl propionate ([11C]PMP)-PET (Irie et al.,
1996). The rate-dependent enzyme for acetylcholine (ACh) degradation
i.e. acetylcholinesterase (AChE) is present at pre- andpostsynaptic neurons
(Wevers, 2011) and in a soluble form at the synaptic cleft (Schegg et al.,
1992).
Studies using [11C]MP4A and [11C]PMP-PET have shown thalamic
cholinergic depletion in PSP (Hirano et al., 2010; Shinotoh et al., 1999)
and cortical cholinergic depletion in CBD (Shinotoh, 2007) and typical
AD. Reduced AChE levels, as measured with [11C]PMP-PET, have also
been found in the neocortex and thalamus in two patients with FTDP-
17 mutations (Hirano et al., 2006).
To date, no PET study investigated the cholinergic system in PPA
exclusively.
The primary objective of this study was to investigate whether
cholinergic alterations occur in PPA and how this depends on the
variant. Cholinergic activity is crucial for several cognitive processes
(Wevers, 2011) and plays a hypothetical role in language (Boban et
al., 2006; Simić et al., 1999). As a consequence, a cholinergic deﬁcit
in PPA may have implications for therapeutic interventions.Table 1
Demographics and neuropsychological characteristics.
Case PPA Post mortem Age (y) Symptom duration (y) Gender C
5b LV / 59 2.5 m 2
6b LV / 77 2 m 1
7b LV / 66 3 m 1
8b LV AD 72 2.5 f 1
13 LV / 57 0.5 f 0
17 LV / 64 3 m 0
23 LV / 71 1 m 0
18 LV / 62 1.5 f 1
1b NFV CBD 77 3 m 1
11b NFV / 71 2.5 m 1
15 NFV / 52 2 f 2
20 NFV / 79 5 f 1
22 NFV / 71 1.5 m 0
26 NFV / 78 2.5 m 1
27 NFV / 72 2.5 f 1
28 NFV / 63 5 f 0
2b SV / 59 4 m 1
3b SV / 63 3 f 1
4b SV / 71 6 m 1
9b SV TDP-43 I 52 1.5 f 1
10b SV / 57 2 m 1
12 SV / 76 6 m 1
14 SV / 70 1.5 f 1
16 SV / 61 3 m 2
19 SV / 64 3 m 1
21 SV / 48 6 f 1
24 SV / 58 2 f 1
25 SV / 68 5 f 1
Groupdata PPA Mean (SD) 65.8(8.5) 2.96(1.5) 13f/15m 0
Controls Mean (SD) 65.4(6.7) / 48f/63m 0
p 0.7 / 0.92 b
Abbreviations: AAT=Aachen aphasia test, comprehension (/120), BORB-hard/-easy=Birming
degeneration, CDR= Clinical dementia rating scale, CPM= colored progressive matrices (/36)
mantic task for words (/30). PPA variants: LV = logopenic variant, NFV = nonﬂuent variant, S
a Scores which are signiﬁcantly different compared to controls based on a modiﬁed t-test.
b Patients who received [11C]PMP-PET.2. Materials and methods
2.1. Subjects
Patients were recruited between 2004–2006 and between 2009 and
2015 at the memory clinic University Hospitals Leuven. Each PPA case
was diagnosed according to Gorno-Tempini et al., 2011 recommenda-
tions (Gorno-Tempini et al., 2011). Healthy control subjects were re-
cruited through advertisement in local newspapers or internet. Eleven
patients with PPA (ﬁve SV, four LV and two NFV) (Table 1) participated
as well as 10 control subjects. Three patients received a neuropatholog-
ical examination (interval from [11C]PMP-PET till death: 6.00 ±
3.61 years). LV case 8 received a diagnosis of pathologically deﬁnite
AD 3 years post [11C]PMP-PET, NFV case 1 a diagnosis of pathologically
deﬁnite CBD 5 years post [11C]PMP-PET and SV case 9 a diagnosis of
pathologically deﬁnite FTLD with TDP-43 inclusions subtype I pa-
thology 10 years post [11C]PMP-PET. There was no signiﬁcant history
of stroke, psychiatric illness or vascular disease in study participants.
Patients were naive for cholinesterase inhibitors and none of the
study participants took anticholinergic medication. All subjects re-
ceived a [11C]PMP-PET scan along with a volumetric MRI scan. For
MRI volumetric comparisons, we included an additional set of 24
healthy controls (67.3 ± 8.83 years), scanned on the same scanner,
as well as 17 additional PPA patients (4 LV, 6 NFV and 7 SV)
(Table 1) (Grube et al., 2016) and 77 additional controls (64.6 ±
5.86 years) who were scanned on a different scanner (seeMRI acqui-
sition and analysis).
The study was approved by the Ethics Committee, University Hospi-
tals Leuven. All participants provided written informed consent in ac-
cordance with the Declaration of Helsinki.DR BNT PALPA AAT-compr BORB-hard BORB-easy CPM
/ 15a 83a 21a 27a 20a
39a 25 102a 22a 30 29
35a 27 94a 23a 32 23a
24a 26 83a 25 29 17
.5 56 28 120 25 29 35
.5 41a 23a 114 25 31 33
53 28 118 26 31 33
53 27 106 24 31 31
43a 25 105 21a 30 24a
45a 29 112 27 30 21a
58 28 120 26 31 31
48 22a 105 25 30 24a
.5 55 28 102a 26 31 24a
48 23a 77a 26 29 30
30a 19a 85a 21a 18a 12a
41a 24a 104a 22a 28 32
36a 22a 78a 17a 23a 21a
14a 24a 95a 22a 25a 23a
13a 22a 95a 24 28 17a
/ 17a 62a 21a 23a 36
14a 22a 87a 19a 26a 34
34a 27 90a 20a 23a 29
22a 17a 74a 20a 18a 24a
7a 18a 73a 18a 20a 36
20a 14a 74a 18a 26a 29
12a 24a 82a 17a 26a 35
35a 27 93a 27 31 36
16a 23a 114 25 31 34
.89 34.3(15.7) 23.4(4.2) 94.5(16.1) 22.6(3.1) 27.4(4.1) 27.6(6.7)
53.7 (4.7) 27.6(1.8) 114.8(4.8) 27.2(1.97) 29.8(1.5) 32.2(3.2)
0.001 b0.001 b0.001 b0.001 b0.001 0.01 0.005
hamobject recognition battery (/32), BNT=BostonNaming test (/60), CBD=corticobasal
, PALPA = Psycholinguistic assessment of language in aphasia, subtest 49: associative-se-
V = semantic variant PPA patients.
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Global cognitive functioning was assessed by the clinical dementia
rating scale (CDR). Language was assessed by means of the 60-item
version of the Boston Naming test (BNT), the validated Dutch version
of the Aachen Aphasia test (AAT) and the verbal semantic association
test of the psycholinguistic assessment of language processing in
aphasia (PALPA subtest 49). Visual recognition of objects was
assessed by the object decision test of the Birmingham object recog-
nition battery (BORB) hard and easy. Fluid intelligence and reason-
ing ability were quantiﬁed by the Raven's colored progressive
matrices (CPM).2.2. PET acquisition and analysis
[11C]PMP was synthesized as described previously (Snyder et al.,
1998). The injected activity was 261.3 ± 28.31 MBq in control subjects
and 290.3± 62.6MBq in PPA patients. Dynamic PET datawere acquired
in 3Dmode during 60min (rebinned in 4 × 15 s, 4 × 1min, 2 × 2.5min,
10 × 5 min) on a Siemens/ECAT EXACT HR+ PET scanner (CTI PET Sys-
tem, Inc., Knoxville, TN 37932, USA). Data were reconstructed using 3D-
ﬁltered back-projection with a Hanning ﬁlter with cut-off frequency of
0.5 of the Nyquist frequency, corrected for random scatter, attenuation
and decay and smoothed with a 6 mm isotropic full-width at half-max-
imum (FWHM) Gaussian 3D kernel.
For each subject 19 arterial samples were collected during the scan
period to determine the individual plasma time-activity curve (TAC).
Seven additional samples were used for metabolite correction. One LV
PPA patient (case 6) (Table 1) and one control subject had to be exclud-
ed due to arterial sampling problems. One control subject was excluded
based on excessivemovement during PET scan acquisition. The remain-
ing eight control subjects and 10 PPA patients were included in our PET-
based analyses.
Blood samples were centrifuged, and the radioactive plasma was
subsequently eluted on high-performance liquid chromatography and
counted in a gamma counter. The intact fractions of tracer over time
were ﬁtted using a constrained Hill model as metabolite correction
function and this function was used to correct the plasma input
function.
PET images were processed using Statistical Parametric Mapping
8 (SPM8, Wellcome Trust Centre for Neuroimaging, London, UK). For
each subject, subject-speciﬁc volumes of interest (VOI) were calcu-
lated by intersecting the subjects normalized gray matter (GM)
map (thresholded at N0.25) with each automatic anatomic labeling
(AAL) (Tzourio-Mazoyer et al., 2002) VOI. With the metabolite-
corrected plasma TACs as input, regional brain TACs were ﬁtted to
the theoretical two-tissue three-rate constant compartment model
including a cerebral blood volume fraction. This model characterizes
rate constants for inﬂux (K1, min−1) and efﬂux (k2, min−1) across
the blood-brain barrier (ﬁrst tissue compartment) and the rate of hy-
drolysis (k3, min−1) of [11C]PMP (second tissue compartment)
(Koeppe et al., 1999). The k3 values were calculated for each sub-
ject-speciﬁc VOI (Fig. A.1). These k3 values are a proxy for AChE activ-
ity levels in the brain (Koeppe et al., 1999). Left and right
hemispheres were analyzed separately. To reduce spillover from
high uptake regions to regions with low or moderate uptake, we ad-
ditionally applied a mask in VOIs with low or moderate uptake. This
mask contained all voxels with high uptake values across all control
subjects and as a result, it excluded these voxels within VOIs with
low or moderate uptake (spill-over correction). We then calculated
a weightedmean k3 value by taking into account the size of each sub-
ject-speciﬁc VOI of the left and right neocortex (including frontal,
parietal, temporal and occipital neocortical VOIs) and left and right
allocortex (including olfactory gyrus, amygdala, hippocampus and
parahippocampal gyrus VOIs) to obtain weighted mean k3 values in
known projection regions of the BF (Mesulam, 2013).2.3. MRI acquisition and analysis
The 11 PPA and 10 HC received a T1-weighted structural MRI on a
1.5T Siemens Sonata system (SiemensMedical Solutions, Erlangen, Ger-
many) and eight-channel head coil (coronal inversion recovery pre-
pared 3D gradient-echo images; inversion time (TI) 800 milliseconds
(ms), echo time (TE) = 3.93 ms, voxel size (1 × 1 × 1) mm3).
Preprocessing of the T1-weighted images was performed with
Voxel-Based Morphometry 8 (VBM8) (Ashburner and Friston, 2000),
implemented in Matlab R2012b as described previously (Gillebert
et al., 2015). This procedure generated non-linear only modulated GM
maps, corrected for total intracranial volumetric differences. These GM
maps were used to obtain mean BF GM volumes by averaging the un-
smoothed modulated warped GM voxel values within the BF mask
(Kilimann et al., 2014). All BF volumes have been adjusted for overall
brain size by using only the nonlinear component of the spatial normal-
ization for modulation of GM voxel intensities.
In order to determine whether any AChE changes occurred speciﬁ-
cally in regions that were typically affected in a particular subtype, an
extended sample of PPA and controls were analyzed to determine the
regions of subtype-speciﬁc atrophy with high sensitivity. In addition
to the initial sample of 11 PPA and 10 control subjects, this extended
sample contained 24 additional controls who had undergone a volu-
metric research MRI on the same scanner using the same sequence as
mentioned above as well as 17 additional PPA (4 LV, 6 NFV and 7 SV)
(Grube et al., 2016) and 77 additional controls who had undergone a
T1-weighted structural MRI on a 3T Philips Intera system and an eight-
channel head coil (coronal inversion recovery prepared 3D gradient-
echo images; TI 900 ms, TE = 4.6 ms, voxel size (0.98 × 0.98 × 1.2)
mm3).
To identify subtype-speciﬁc atrophy, we contrasted the group of 28
PPA cases to the 111 controls in a voxelwise ANCOVA in SPM8 with
smoothed modulated GM volume maps as within-subject factor,
group (4 levels: LV, SV, NFV, healthy controls) as between-subject factor
and age, gender and scanner as nuisance variables. Results were consid-
ered signiﬁcant at voxel-level uncorrected p b 0.001 combined with
cluster-level family-wise error (FWE)-corrected p b 0.05 (Poline et al.,
1997). For voxelwise statistical comparisons, GMmaps were smoothed
with an 8 mm isotropic FWHM Gaussian 3D kernel.2.4. Statistics
Standard statistical analyses were performed in Statistics Software
Package for the Social Sciences (version 23, IBM Statistics, Armonk,
USA).
BF volumes and AChE activity levels were checked for outliers using
the Grubbs' test: Z scores higher than three standard deviations were
classiﬁed as outliers. The individuals' Neuropsychological test scores
were compared to controls using a modiﬁed t-test (Crawford and
Garthwaite, 2012) (Table 1). Differences in age between PPA patients
and control subjects were assessed using Kruskal-Wallis andwith Pear-
son chi2 tests for gender.2.4.1. Primary outcome analyses
Given the relatively limited sample size, the primary analysis was
based on a multiple single case series methodology. Differences of
AChE activity levels in global neo- and the global allocortical VOIs in
the left and right hemisphere were assessed in each individual patient
in comparison to the eight controls using a modiﬁed t-test (Crawford
and Garthwaite, 2012).
As a second primary outcome analysis, a Spearman or Pearson corre-
lational analysis was performed between AChE activity levels averaged
over left and right allo- and neocortex, and BF volume, depending on
normality of the data.
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Secondary outcome analyses aimed to evaluate effects at the overall
group and at the subgroup level, to examine the relationship between
the AChE activity levels and structural changes, and to test the replica-
bility of the BF atrophy in PPA reported previously (Teipel et al., 2016,
2014).
1. Differences in AChE activity were assessed at the group level (PPA
versus controls) using Kruskal-Wallis and with post hoc Mann-
Witney U tests for differences between subgroups (uncorrected,
two-tailed p values).
2. In order to evaluate the relationship between AChE activity levels
and structural atrophy, AChE activity levels were calculated in each
individual patient compared to controls in the regions that were
characteristically atrophic for the subtype to which the case
belonged (LV, NFV or SV) (VOI shown in Fig. 3). In order to determine
whether AChE activity levels were speciﬁcally lower in the atrophic
regions, AChE activity levels were also evaluated in cortical regions
falling outside subtype-speciﬁc regions of atrophy. The latter region
was determined by subtracting the region of characteristic atrophy
from the subjects normalized GM map (thresholded at N0.25). For
each individual patient, differences in AChE levels compared to con-
trols were assessed using a modiﬁed t-test.
3. In order to evaluate whether BF volume decreases that have previ-
ously been reported (Teipel et al., 2016, 2014) could be replicated,
a BF volume analysis was performed in the extended sample of 28Fig. 1. Acetylcholinesterase activity levels. AChE activity levels are plotted for (A) left and (B)
median (red line), third quartile, and maximum. Color bar: t scores for individual AChE a
signiﬁcantly differed from controls based on the modiﬁed t-test are indicated with an aster
amy = amygdala, HC = healthy controls, hip = hippocampus, LV = logopenic variant, NFV =
variant PPA patients, tot = total region. Case nr. = case numbers corresponding to Table 1.PPA and 111 control subjects. Bymeans of an ANCOVAmodel, BF vol-
umes were assessed at the group level in controls, LV, NFV and SV
PPA with scanner type as nuisance variable, and post hoc Bonferroni
correction for the number of comparisons at α= 0.05.
4. Finally, we determined the effects of symptom duration, age, and
gender on AChE activity levels bymeans of Spearman or Pearson cor-
relational analyses or Mann Witney U tests (two-tailed).
3. Results
3.1. Primary outcome analyses
3.1.1. AChE activity levels in PPA patients
Two out of three LV patients showed signiﬁcantly lower neocortical
AChE activity levels than controls in the left (case 7: t = −2.68, p =
0.016 and case 8: t=−4.12, p=0.002) (Fig. 1A) and in the right hemi-
sphere (case 7: t=−3.17, p=0.008 and case 8: t=−5.59, p b 0.001)
(Fig. 1B). No differences were found in NFV or SV cases compared to
controls (all p N 0.13) (Fig. 1A, B).
In two out of three LV patients, left allocortical AChE activity levels
were signiﬁcantly lower than in controls (case 7: t = −1.93, p =
0.047 and case 8: t = −2.70, p = 0.015) (Fig. 1C). In one of these
cases, right-hemispheric allocortical AChE activity levels were also
lower compared to controls (case 8: t=−4.20, p= 0.002) (Fig. 1D).
Four out of ﬁve SV patients showed signiﬁcantly elevated right
allocortical AChE activity levels (case 3: t = 3.39, p = 0.006; case 4:
t = 4.57, p = 0.001; case 9: t = 2.26, p = 0.029; case 10: t = 3.28,right neocortex and for (C) left and (D) right allocortex. Boxplot: minimum, ﬁrst quartile,
ctivity levels based on a modiﬁed t-test with a threshold of α = 0.05. Patients who
isk on the color bar. For group based comparisons: *p b 0.05, **p b 0.01. Abbreviations:
nonﬂuent variant, olf = olfactory gyrus, phg = parahippocampal gyrus, SV = semantic
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levels were signiﬁcantly higher than in controls (case 10: t = 2.0, p=
0.042) (Fig. 1C). No signiﬁcant differences compared to controls were
found in NFV patients (all p N 0.37).
In order to gain further insight in the elevation of allocortical AChE
activity levels in SV cases, we analyzed each of the four subVOIs of
which the allocortical VOIwas composed. The elevation of AChE activity
was mainly seen in the subVOI corresponding to the right
parahippocampal gyrus (case 3: t = 3.72, p = 0.004, case 4: t = 5.22,
p b 0.001, case 9: t = 2.11, p = 0.036 and case 10: t = 3.93, p =
0.003) and least so in the subVOI corresponding to the olfactory gyrus
(case 9: t= 1.95, p= 0.046) (Fig. 1C and D).
3.1.2. Correlation between BF volume and AChE activity levels
BF volume in PPA patients did not correlate with AChE activity levels
in the left (Spearman ρ(8) = 0.16, p= 0.65) or right neocortex (Pear-
son ρ(8) =−0.37, p = 0.29) (Fig. 2A and B), nor in the left (Pearson
ρ(8) = −0.24, p = 0.51) or right allocortex (Pearson ρ(8) = 0.28,
p= 0.43) (Fig. 2C and D).
3.2. Secondary outcome analyses
3.2.1. Group-based comparisons of AChE activity levels in neo- and
allocortex
Left neocortical AChE activity differed signiﬁcantly between groups
(chi2(3) = 9.5, p = 0.024). Only LV patients showed signiﬁcantly
lower left neocortical AChE activity levels compared to controls (U =
2, p= 0.041) and compared to SV patients (U= 0, p= 0.025). No dif-
ferences were found between other subgroups (all p N 0.053) (Fig.
2A, B).
Right allocortical AChE activity levelswere signiﬁcantly different be-
tween groups (chi2(3)=11.3, p=0.010) (Fig. 2D). SV patients had sig-
niﬁcantly elevated right allocortical AChE activity levels compared to
controls (U = 0, p = 0.003) and compared to LV (U = 0, p = 0.025).Fig. 2. Basal forebrain volume and AChE activity levels. AChE activity levels of (A) left and (B) rig
forebrain volumes (arbitrary units) on the ordinate. Green diamonds: HC= healthy controls, b
SV = semantic variant PPA patients. Case numbers correspond to Table 1.No signiﬁcant differences were found between other subgroups (all
p N 0.053).
3.2.2. Topography of AChE activity changes versus topography of cortical
volume loss in PPA
3.2.2.1. Deﬁnition of PPA atrophic regions. In the extended sample of PPA
patients and controls, LV patients showed atrophy restricted to the
left posterior third of the left middle temporal gyrus, extending to-
wards the temporoparietal junction as well as bilateral atrophy of
the precuneus (Fig. 3A). NFV patients exhibited atrophy of the bi-
lateral supplementary motor area and cingulum, together with
left inferior and middle frontal lobe atrophy extending towards
the left insula (Fig. 3B). SV patients showed severe atrophy of the
bilateral anterior temporal lobe, including the anterior fusiform
gyri, as well as atrophy of the amygdalae, hippocampi and insulae
(Fig. 3C).
Overall, there was a predominant left lateralization of atrophy inde-
pendently of PPA subtype.
3.2.2.2. AChE activity levels in the PPA atrophic and preserved neocortical
regions. At the individual patient level, two out of three LV patients
showed lower AChE activity levels compared to controls in brain re-
gions typically atrophic in LV PPA (case 7: t =−2.65, p = 0.016 and
case 8: t=−6.20, p b 0.001) (Fig. 4A). These two LV patients showed
also lower AChE activity levels (case 7: t=−3.04, p= 0.009 and case
8: t = −4.73, p = 0.001) compared to controls outside the regions
that were typically atrophic in LV PPA (Fig. 4B). This suggests that the
reduction in AChE activity levels is not restricted to the regions of char-
acteristic atrophy in LV but is more diffuse.
Compared to controls, two of the ﬁve SV patients showed elevated
AChE activity levels in regions typically atrophic in SV PPA (case 9:
t= 2.09, p= 0.038; case 10: t= 1.88, p= 0.05) (Fig. 4A). SV patients
did not show abnormal AChE activity levels outside the SV atrophicht neocortex and (C) left and (D) right allocortex on the abscissa (min−1) andmean basal
lack triangles: LV = logopenic variant, red squares: NFV= nonﬂuent variant, blue circles:
Fig. 3. Cortical atrophy patterns in PPA. T-maps, generated by contrasting each PPA subgroup (total N=28) versus controls (N=111) in SPM8, are projected onto a surface rendering of a
template brain andon coronal sliceswith correspondingMNI coordinates. Threshold: voxel-level uncorrectedp b 0.001 combinedwith cluster-level FWE-corrected p b 0.05. T-maps depict
brain regions of reduced gray matter volume in (A) logopenic variant (LV), (B) nonﬂuent variant (NFV), and (C) semantic variant (SV) PPA patients.
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levels in SV could potentially be most pronounced in those regions
that are also most affected structurally. No signiﬁcant differences were
found for NFV patients compared to controls (all p N 0.31).
3.2.3. BF volumetry in the extended PPA sample
In the entire group of PPA patients, BF volume was reduced in three
out of eight LV (case 5: t=−1.75, p= 0.042, case 7: t =−2.41, p=
0.009 and case 17: t =−2.00, p = 0.023), one out of eight NFV (case
11: t = −1.91, p = 0.029) and ﬁve out of 12 SV patients (case 2,Fig. 4. AChE activity levels in subtype-speciﬁc PPA atrophic regions and in the associative-sema
subtype-speciﬁc atrophy in PPA and (B) complementary non-atrophic brain regions. Note that
for each subtype are obtained in the regions that are atrophic for that particular subtype. Accord
region. Patients that signiﬁcantly differed from controls are indicated with an asterisk on the c
variant, SV = semantic variant. Case numbers correspond to Table 1.t = −3.42, p b 0.001, case 9: t = −1.91, p = 0.029, case 14:
t = −2.45, p = 0.008, case 19: t = −2.56, p = 0.006 and case 25:
t=−3.07, p= 0.001) compared to controls (Fig. 5).
There was a signiﬁcant overall effect of group on BF volume (F
(3134) = 11.8, p b 0.001). Post hoc tests revealed that BF volume was
most reduced in SV compared to controls (−17.2 ± 11%, p b 0.001).
No signiﬁcant differences were found in LV (−7.3 ± 13%, p = 0.40)
or NFV (−9.6 ± 7.8%, p= 0.07) patients compared to controls. No sig-
niﬁcant differences of BF volume were found between PPA variants
(p N 0.1) (Fig. 5).ntic network. AChE activity based on a modiﬁed t-test with a threshold of α=0.05 in (A)
the subtype-speciﬁc regions differed depending on the variant and that the values plotted
ingly, the corresponding values in the controlswere obtained in that same subtype-speciﬁc
olor bar. Abbreviations: LV = logopenic variant, HC = healthy controls, NFV = nonﬂuent
Fig. 5. Basal forebrain volume in PPA subtypes. Boxplot with BF volumes: minimum, ﬁrst quartile, median (red line), third quartile, andmaximum and color bar: t scores for individual BF
volume based on a modiﬁed t-test with a threshold of α= 0.05. Patients that signiﬁcantly differed from controls are indicated with an asterisk on the color bar. For group based
comparisons: ***p b 0.001. Abbreviations: HC = healthy controls, LV = logopenic variant, NFV = nonﬂuent variant, SV = semantic variant PPA patients. Case numbers correspond to
Table 1.
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In the current PPA sample, there were no effects of symptom dura-
tion on AChE activity levels in the left or right neo- or allocortical region
(p N 0.30) and no effects of age (p N 0.098) or gender (p N 0.57) on AChE
activity levels.
4. Discussion
The current ﬁndings demonstrate that BF atrophy does not imply
cholinergic depletion. The presence of BF atrophy in SV was replicated,
however this was not associated with a cholinergic deﬁcit. Instead
AChE activity in SV was increased. Cholinergic depletion was only
seen in LV cases, both within and outside the neocortical regions of
characteristic atrophy.
4.1. Cholinergic alterations
The LV with pathologically deﬁnite AD (case 8) showed the stron-
gest reductions in AChE activity levels. LV PPA can occur as an atypical
variant of AD and 50–60% of cases show AD pathology (Matías-Guiu et
al., 2015). Loss of the cholinergic systems integrity is among the earliest
events in the pathogenesis of typical AD: several studies have shown re-
duced AChE activity in typical AD patients using [11C]PMP-PET (Bohnen
et al., 2005, 2003; Kuhl et al., 1999). The current study shows that this
ﬁnding can be extended to a subset of LV PPA cases.
The reduction in AChE activity did not appear to be limited to regions
typically affected by volume loss in LV PPA. AChE activity reductions
were seen also outside regions of typical atrophy. If AChE activity reduc-
tions in LV are a consequence of neuronal loss in diffusely projecting
subcortical nuclei such as Ch4, one would expect that the PET measure
would not strictly overlap with the measure of regional volume loss.
Unexpectedly, despite the BF volume loss, SV PPA was associated
with an increase in AChE activity levels. This increase was most pro-
nounced in regions of maximal volume loss, both in the neocortical
and in the allocortical regions such as the parahippocampal gyrus. The
colocalisation between AChE activity increases and structural volume
loss could possibly suggest that AChE activity increases are a compensa-
torymechanism and a reaction to neuronal loss in SV PPA. This increasewas only observed in SV cases and the vast majority of SV PPA is caused
by a TDP-43 proteinopathy (Grossman, 2010; Josephs et al., 2009). In
the current study, SV case 9 received a diagnosis of pathologically deﬁ-
nite FTLDwith TDP-43 inclusions subtype I. A previous expression study
in transgenic mice (Tg-VLW) expressing human tau mutations, sug-
gested that tauopathy may be associated with AChE activity increases
(Silveyra et al., 2012). This is the ﬁrst study which showed AChE in-
creases in a casewith proven TDP-43 proteinopathy. It may beworth in-
vestigating how speciﬁc types of proteinopathy differentially affect
neurotransmitter systems and the regional speciﬁcity of such effects.
Neuropathological examinations of other cholinergic biomarkers in
semantic dementia showed that there is an increase in the proportion
of cholinergicM2muscarinic receptors compared to controls, with a de-
crease in the proportion of cholinergic M1 muscarinic receptors
(Odawara et al., 2003). The increase in M2 receptors found by Odawara
as well as the increase in AChE activity levels in the current study are
possibly suggesting a compensatory reaction to the neurodegenerative
neuronal loss.
Elevated AChE activity levels as measured with PET have previously
been reported in FTD, although non-signiﬁcantly and restricted to the
thalamus (Hirano et al., 2010). However, most studies on FTD failed to
show any abnormalities in AChE, be it post mortem (Procter et al.,
1999) or at the level of cerebrospinal ﬂuid (CSF) (Wallin et al., 2003).
4.2. BF atrophy and relation to cholinergic alterations
The BF receives afferents from the amygdala and hippocampus
(Aggleton et al., 1987). On their turn, cholinergic pathways arising
from the BF project among others to the temporal lobe and the
parahippocampal gyrus (Selden et al., 1998). These regions are typically
affected in SV PPA in cross-sectional (Mummery et al., 2000; Rosen et
al., 2002; Whitwell et al., 2005) and longitudinal studies of the disease
(Brambati et al., 2007).
BF volume loss in SV however was not associated with cholinergic
depletion. The neuronal, glial and interstitial compartments that con-
tribute to MRI measures of BF are far broader than the cholinergic neu-
ronal cell population. For instance, cholinergic neurons are typically
found intermingled with inhibitory interneurons, the second most im-
portant BF cell types (Mesulam, 2013).
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sures with regards to cholinergic status in PPA.4.3. A cholinergic therapy for PPA?
There are currently no medications approved by the US Food and
Drug Administration (FDA) to treat PPA. Language regions contain a rel-
atively high density of AChE-containing neurons (Hutsler and
Gazzaniga, 1991), which may suggest a rational basis for cholinergic
treatment in PPA. Cholinergic therapy improves language in various dis-
orders affecting the language network (Berthier et al., 2006; Ferris and
Farlow, 2013; Tanaka et al., 1997; Yoon et al., 2015), although regulatory
approval is restricted to clinically probable AD.
To date, only one study with an open-label period of 18weeks and a
randomized, placebo- controlled phase for eight weeks with galanta-
mine included PPA patients (Kertesz et al., 2008). The overall language
performance showed a trend towards stabilization over a total duration
of eight weeks. A randomized, placebo- controlled study with
memantine showed general good tolerance, however there were more
frequent cognitive adverse events (Boxer et al., 2013). A therapeutic
trial of donepezil in FTD failed to show any efﬁcacy and a subgroup of
patients experienced worsening of symptoms (Mendez et al., 2007).
Currently, cholinergic medication may be prescribed off-label in
clinical practice for PPA patients who are amyloid positive (amyloid-
PET or CSF amyloid/tau). AChE-PET allows one to directly discriminate
PPA cases with a cholinergic deﬁcit from those without a cholinergic
deﬁcit. This distinction could possibly predict a therapeutic response,
but this remains to be demonstrated. The cholinergic deﬁcit in LV in
the current study provides a potential rationale for off-label use of
AChE inhibitors (AChEI) in LV PPA due to underlying AD pathology.
However our ﬁndings do not provide direct support for the use of
AChEI in SV PPA, since AChE activity appears to be already naturally in-
creased in this subtype compared to healthy controls.4.4. Potential study limitations
The number of PPA patients included is small. This is inherent to the
relatively high demands of the scanning procedures, in particular for dy-
namic PET acquisition with arterial sampling, and the relatively low
prevalence of PPA (Gorno-Tempini et al., 2011). We calculated k3 as
index for AChE activity based on the well-established theoretical two-
tissue three-rate constant compartment model with a cerebral blood
volume fraction (Koeppe et al., 1999). Cerebral atrophy does not inﬂu-
ence the rate constants including k3, nor does k3 depend on blood ﬂow
or aging (Kuhl et al., 1999). Based on the compartmentmodel used, par-
tial volume effects on k3 are negligible if spillover from neighboring re-
gions can be neglected (Koeppe et al., 1999; Kuhl et al., 1999). The
effects of butyrylcholinesterase (BChE), which has been shown to in-
crease in the course of neurodegenerative diseases (Nordberg et al.,
2013), on the k3 values are also negligible (Kuhl et al., 1999).
The diffuse structure of the BF itself may cause difﬁculties to reliably
delineate its borders on MRI. We therefore used the BF mask obtained
with a procedure of Kilimann (2014) based on histological staining of
post mortem brain sections which were subsequently transferred to
MNI space (Kilimann et al., 2014). Given the small volume of each
subnucleus, we decided to assess the BF volume as one single volume
as this provided a more robust estimation. The distribution of the cur-
rent BF mask used in this study was compared to two previous masks,
one based on a single subject (Teipel et al., 2005), and one probabilistic
map based on 10 subjects (Zaborszky et al., 2008) in a study of Teipel
and colleagues (Teipel et al., 2016). Therewas a high general agreement
between all threemasks. These ﬁndings suggest that the anatomy of the
BF nuclei delineated by means of this procedure is relatively stable
across subjects.5. Conclusion
We established involvement of the cholinergic system in PPA, both
at the structural and functional level. The observed cholinergic deﬁcit
further encourages development of cholinergic PPA treatments in LV,
possibly in NFV but not in SV PPA cases.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nicl.2016.11.027.
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